167 results
Page 2 of 9
8-K
EX-99.3
f2sz3smqwq9i5l7 8rl4
11 Dec 20
Lexicon Announces Offering of Common Stock
5:28pm
424B5
emaegq1tm exd6taib6
11 Dec 20
Prospectus supplement for primary offering
8:02am
424B5
v4970s9 ml
30 Oct 20
Prospectus supplement for primary offering
5:11pm
8-K
0wed 10yj1
8 Sep 20
Termination of a Material Definitive Agreement
5:02pm
8-K
EX-99.1
31oepxb
30 Jul 20
Lexicon Pharmaceuticals Enters into Agreement
7:18am
8-K
EX-99.1
02bwxvnpvcthk 6bzo
30 Jul 20
Lexicon Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides a Business Update
7:04am
8-K
grbsq 1g8v3vtsolm
29 May 20
Termination of a Material Definitive Agreement
4:33pm
8-K
EX-99.1
3pj1vf b9
27 Apr 20
Lexicon Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides a Business Update
7:04am
DEFA14A
lrasts0 jqiptdu7x5jk
7 Apr 20
Additional proxy soliciting materials
4:57pm
8-K
EX-99.1
6mohvaodz769egvtupn
12 Mar 20
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-year 2019 Financial Results and Provides a Business Update
7:04am
8-K
EX-99.1
byu8heewub o382b
7 Nov 19
Lexicon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides a Business Update
7:06am
8-K
EX-99.1
g1axjg8
10 Sep 19
Lexicon Pharmaceuticals Announces Termination of Alliance and Settlement with Sanofi
4:03pm
8-K
EX-99.1
pdvxl3 h1wzs
31 Jul 19
Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update
7:11am
8-K
EX-99.1
qhu9nhqh7 xh53i
29 Jul 19
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquistatm (Sotagliflozin) Type 2 Diabetes Phase 3 Program
12:00am
8-K
EX-99.1
2ana 3ieuh9bis7d
1 May 19
Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update
7:17am